AstraZeneca is making a major push into cell therapy with the acquisition of EsoBiotec, a company that has developed a ...

Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, ...

(Reuters) -Drugmaker AstraZeneca said on Monday it will buy biotechnology firm EsoBiotec for up to $1 billion. EsoBiotec's ...

British drug major AstraZeneca said on Monday it has entered into a definitive agreement to acquire EsoBiotec, a Belgian ...

The deal includes the Belgian biotech’s in-vivo cell-therapy platform, which modifies immune cells within the patient’s body, ...

EsoBiotec SA has entered into a definitive agreement to be acquired by AstraZeneca ( NASDAQ: AZN) for up to $1 billion, on a ...

AstraZeneca has agreed to purchase Belgium-based EsoBiotec for up to $1 billion. The acquisition is aimed at enhancing ...

The transaction is expected to close in the second quarter of 2025, which will include AstraZeneca will buying all ...

The deals are expected to shorten manufacturing timelines for cell therapies and reduce administration times for oncology ...

AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1,000m, on a cash and debt free basis. This will include an initial payment of $425m on deal closing, ...

British-Swedish multinational pharmaceutical and biotechnology company AstraZenica on Monday announced the acquisition of ...

AstraZeneca already has cell therapies in its pipeline, and it is now expanding its scope further with a deal to acquire EsoBiotec, a company in early clinical development with therapies made by ...